Can Dupixent (dupilumab) be used off‑label for chronic obstructive pulmonary disease (COPD), and what dosing regimen is recommended?

Dupixent for COPD: FDA-Approved with Specific Criteria

Dupixent (dupilumab) is now FDA-approved for COPD and should be used as add-on maintenance therapy in adult patients with inadequately controlled COPD and an eosinophilic phenotype at a dose of 300 mg subcutaneously every 2 weeks. 1

FDA-Approved Indication and Dosing

The FDA label explicitly states that Dupixent is indicated for "add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype." 1 This is not off-label use—it is a formal FDA indication as of 2026.

Dosing regimen: 300 mg subcutaneously every other week (Q2W), with no loading dose required for COPD patients. 1

Important limitation: Dupixent is NOT indicated for relief of acute bronchospasm. 1

Patient Selection Criteria

Based on the pivotal trials (BOREAS and NOTUS) that led to FDA approval, Dupixent should be prescribed for COPD patients meeting these criteria:

• Blood eosinophil count ≥300 cells/μL at screening 2, 3, 4
• Already on maximal triple inhaled therapy (ICS/LABA/LAMA) 2, 3, 4
• Inadequate control despite triple therapy, defined as:
  • At least 2 moderate exacerbations OR
  • At least 1 severe exacerbation in the previous year 2, 3
• Post-bronchodilator FEV1 30-70% predicted 2, 3
• Post-bronchodilator FEV1/FVC ratio <0.7 2, 3
• Symptomatic COPD with chronic productive cough for ≥3 months in the previous year 4

Clinical Evidence Supporting Use

The pooled analysis of BOREAS and NOTUS trials (n=1,874 patients) demonstrated robust efficacy 4:

• 30% reduction in moderate/severe exacerbations (annualized rate 0.794 vs 1.156 with placebo; p<0.0001) 4
• Improved lung function: FEV1 increased by 82 mL at week 12 (p<0.001) and sustained at 62 mL at week 52 2, 3
• Reduced time to first severe exacerbation (39% risk reduction; p=0.016) 4
• Improved quality of life: SGRQ score improved by 3.4 points more than placebo (p=0.002) 2
• Reduced symptom burden: E-RS-COPD score improved by 1.1 points more than placebo (p=0.001) 2

Real-world data from a single-center study showed even more dramatic short-term effects at 4 weeks, including significant lung deflation (residual volume decreased from 4.17 to 3.47 L; p<0.05) and improvements in small airway function. 5

Efficacy Across COPD Phenotypes

Dupilumab works equally well regardless of emphysema status—a post-hoc analysis of BOREAS showed similar exacerbation reductions (29-31%) and FEV1 improvements in patients with and without investigator-reported emphysema, with no treatment-by-emphysema interaction. 6

Safety Profile

Dupilumab was well-tolerated in COPD trials with a safety profile consistent with its use in other type 2 inflammatory conditions 2, 3, 4:

• Treatment-emergent adverse events, serious adverse events, and discontinuations were similar between dupilumab and placebo groups
• Most common adverse events: injection site reactions (typically mild) 7
• Monitor for: conjunctivitis and keratitis (more common in atopic dermatitis but can occur) 1
• Contraindication: Known hypersensitivity to dupilumab 1

Practical Implementation

Administration:

• Subcutaneous injection into thigh, abdomen (avoiding 2 inches around navel), or upper arm 1
• First 2 injections should be administered in a clinical setting for training and monitoring 8
• Subsequent injections can be self-administered by patient or caregiver 1
• Rotate injection sites with each dose 1

Missed doses: If a Q2W dose is missed, administer within 7 days and resume original schedule; if >7 days late, wait until next scheduled dose. 1

Storage: Refrigerate; allow to reach room temperature for 45 minutes before injection. Once removed from refrigerator, must be used within 14 days. 1

Positioning in COPD Treatment Algorithm

Traditional COPD guidelines 9, 10 recommend escalating from LABA/LAMA to triple therapy (LABA/LAMA/ICS) for patients with persistent exacerbations. When triple therapy fails, options historically included:

• Adding roflumilast (for FEV1 <50% with chronic bronchitis) 9
• Adding macrolides in former smokers 9
• Pulmonary rehabilitation 9

Dupixent now provides a targeted biologic option for the specific subset of COPD patients with type 2 inflammation (eosinophilic phenotype) who remain uncontrolled on triple therapy. This represents precision medicine in COPD management.

Key Clinical Considerations

Do NOT use Dupixent if:

• Blood eosinophils <300 cells/μL (no evidence of benefit)
• Patient has asthma rather than COPD (different indication and potentially different dosing)
• Patient is not already on optimized triple inhaled therapy
• For acute exacerbation management (use systemic corticosteroids and antibiotics per guidelines 11)

Important distinction from asthma: Recent NICE guidance for dupilumab in COPD differs from asthma criteria, creating potential management challenges for patients with asthma-COPD overlap. 12 For pure COPD, follow the eosinophil ≥300 cells/μL threshold; for asthma-COPD overlap, clinical judgment is needed regarding which treatment pathway to follow.

Biomarker monitoring: Blood eosinophils typically decrease significantly within 4 weeks (from ~390 to ~190 cells/μL in real-world data), along with reductions in basophils, fibrinogen, and FeNO. 5 These changes correlate with clinical improvement.